CSI Market
Sign In | Register

Caribou Biosciences Inc (CRBU) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access CRBU quarterly Cash Flow →
The data below summarizes Caribou Biosciences Inc's cash flow activity from Dec 31 2021 to Dec 31 2025, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-148.13
Depreciation & amortization3.65
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Asset Impairment Charges12.15
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets, Total-0.03
Share-based Compensation12.68
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Equity Securities Fv Ni Gain Loss0.10
Non Cash Consideration For Licensing And Collaboration Revenue-0.01
Change In Fair Value Of Success Payments Liability-0.79
Research And Development Expense Software Excluding Acquired In Process Cost-
Extinguishment Of Debt Gain Loss Net Of Tax-
Increase Decrease In Contract With Customer Asset0.15
Increase Decrease In Deferred Rent And Lease Incentive Liability-
Increase Decrease In Contract With Customer Liability-2.80
Non Cash Lease Expense1.84
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.12
Increase (Decrease) in Accounts Payable3.25
Increase (Decrease) in Accrued Liabilities-6.34
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets3.68
Other Working Capital2.80
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities6.67
Discontinued operations0.00
Net Cash flow from Operating Activities-110.99
Investing Activities
Capital Expenditures-1.36
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities252.83
Payments to Acquire Marketable Securities-149.23
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities102.24
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock4.82
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-16.39
Payment Of Deferred Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations-
Restricted Cash And Cash Equivalents At Carrying Value0.05
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents16.34
Proceeds From Exercise Of Stock Options And Purchases Of Common Stock Under Employee Stock Purchase Plan0.01
Finance Lease Principal Payments-
Proceeds From Issuance Of Follow On Public Offering-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities4.82
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-112.35
Total Cash Flow-3.93
4 historic quarters locked

Sign in to unlock the full Caribou Biosciences Inc cash flow history.

Sign In Create Free Account

About Caribou Biosciences Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001619856-26-000008

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License